# US 2012/0252839 A1 · Gain-of-function bcl-2 inhibitors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0252839 A1
- Document ID: US20120252839A1
- Status: Published application
- Kind: A1
- Application number: 13/437,795
- Filed: 2012-04-02
- Published: 2012-10-04
- Earliest claimed: 2009-10-02
- Assignees: Fred Hutchinson Cancer Research Center
- Inventors: David HOCKENBERY; Julian SIMON
- Web page: https://patentgrep.com/patent/US20120252839A1

## CPC

- C07D 401/12: linked by a chain containing hetero atoms as chain links
- C07C 235/60: having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C 251/86: having doubly-bound carbon atoms of hydrazone groups bound to carbon atoms of six-membered aromatic rings
- C07C 323/20: with singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
- C07D 213/77: Hydrazine radicals
- C07D 217/22: with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D 271/08: 1,2,5-Oxadiazoles; Hydrogenated 1,2,5-oxadiazoles
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS

## Abstract

Compounds are described that are useful for treating an apoptosis-associated disease, which are specifically cytotoxic to tumor cells that are overexpressing Bcl-xL, and are much less cytotoxic in isogenic cells that are not overexpressing Bcl-xL. Also described is a method for treating an apoptosis-associated disease in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of an active compound that is specifically cytotoxic to tumor cells that are overexpressing Bcl-xL, and are much less cytotoxic in isogenic cells that are not overexpressing Bcl-xL. Several scaffolds of active compounds are described.

## Claims

### Claim 1

An isolated compound consisting of Formula I
wherein:
R1 is OH, Cl, or methoxy;
R2 is H, NO2, Br, t-butyl, or methoxy;
R3 is H, methyl, or t-butyl;
R4 is H, Cl, Br, t-butyl, or methyl
R5 is H, Cl or OH; and
X is —NH—R6; —[C═O]—R6; or —NH—[C═O]—R6—;
wherein R6 is
A is CH or N;
R7 is H, NO2, or CF3; and
R8 is H or Cl;
or a salt, or a prodrug or a prodrug salt; or a hydrate or a solvate or a polymorph of any of the foregoing.

### Claim at position 2

2-3. (canceled)

### Claim 4 (depends on 1)

The compound of claim 1, selected from the group consisting of
and wherein the active compound has an IC50 less than 5 micromole/liter (5 μM) in cells overexpressing Bcl-xL, and at least 20-fold less cytotoxic in isogenic cells that are not overexpressing Bcl-xL.

### Claim 5

(canceled)

### Claim 6 (depends on 1)

The compound of claim 1, selected from the group consisting of:
wherein the active compound has an IC50 less than 3 μM in cells overexpressing Bcl-xL.

### Claim 7

(canceled)

### Claim 8 (depends on 1)

The compound of claim 1, selected from the group consisting of
wherein the active compound has an IC50 less than 5 micromole/liter (5 μM) in cells overexpressing Bcl-xL, and at least ten-fold less cytotoxic in isogenic cells that are not overexpressing Bcl-xL.

### Claim 9

(canceled)

### Claim 10 (depends on 1)

The compound of claim 1, selected from the group consisting of:
wherein the active compound has an IC50 less than about 3 μM in cells overexpressing Bcl-xL.

### Claim 11

(canceled)

### Claim 12 (depends on 1)

The compound of claim 1, selected from the group consisting of:
wherein the active compound has an IC50 less than 5 micromole/liter (5 μM) in cells overexpressing Bcl-xL, and at least five-fold less cytotoxic in isogenic cells that are not overexpressing Bcl-xL.

### Claim at position 12

13-15. (canceled)

### Claim 16 (depends on 1)

The compound of claim 1, consisting
wherein the active compound has an IC50 less than 3 micromole/liter (5 μM) in cells overexpressing Bcl-xL, and at least three-fold less cytotoxic in isogenic cells that are not overexpressing Bcl-xL.

### Claim at position 14

17-19. (canceled)

### Claim 20 (depends on 1)

The compound of claim 1, selected from the group consisting of:
wherein the active compound has an IC50 less than 5 micromole/liter (5 μM) in cells overexpressing Bcl-xL, and at least two-fold less cytotoxic in isogenic cells that are not overexpressing Bcl-xL.

### Claim at position 16

21-22. (canceled)

### Claim 23

A compound consisting of the structure of Formulas II or III,
wherein;
R1 is H, OH, OMe, OAc, or O(C═O)CMe2;
R2 is H, OH, OMe, or OAc;
R3 is H, OH, OMe, OAc, or O(C═O)CMe2
R4 is H, Me, or Cl
R5 is H, Me, or Cl;
R6 is H; and
A is CH2, or O, and
wherein the active compound has an IC50 less than 5 micromole/liter (5 μM) in cells overexpressing Bcl-xL.

### Claim at position 18

24-40. (canceled)

### Claim 41 (depends on 1)

A method for treating an apoptosis-associated disease in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of an active compound according to claim 1.

### Claim 42

A method for treating an apoptosis-associated disease in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of an active compound of Formula IV, V, or VI:
wherein
A is S, CH2, SO, or SO2;
R1 is H, Br, Cl, methyl, t-butyl, methyl chloride, methyl alcohol
R2 is H, Cl, methyl or t-butyl;
R3 is H, OH, or methyl;
R4 is H, Cl, Br, or methyl; and
R5 is H, Br, Cl, methyl, or t-butyl, and
wherein the active compound has an IC50 less than 10 μM in cells overexpressing Bcl-xL.

### Claim at position 21

43-50. (canceled)

### Claim 51

A method for treating an apoptosis-associated disease in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of an active compound of Formula VII:
wherein
R1 is hydroxyl, NO2, or an oxadiazole formed with R2;
R2 is H or an oxadiazole formed with R1;
R3 is H, or NO2;
R4 is H or Cl; and
R5 is 2-OH-5-Cl-phenyl-, —CH2-phenyl, 4-isopropyl-phenyl-, 2,4-dinitrophenyl-, or 2-chlorocyclohexane, and
wherein the active compound has an IC50 less than 15 micromole/liter (15 μM) in cells overexpressing Bcl-xL.

### Claim at position 23

52-53. (canceled)

### Claim 54 (depends on 51)

The method of claim 51, wherein the compound is:

### Claim at position 25

55-60. (canceled)
